Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
06 June 2018 - 10:45PM
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel cell and gene
therapies for life-threatening rare genetic diseases, today
announced CEO, Carsten Thiel, Ph.D., will present at the at the
Jefferies 2018 Global Healthcare Conference in New York City, NY.
Event: Jefferies 2018 Global Healthcare
ConferenceDate: Thursday, June
7thPresenter: Carsten Thiel, Ph.D.,
CEOPresentation Time: 11:00 AM – 11:25 AM
ETRoom Name: Ballroom ILocation:
New York City, NYWebcast:
http://wsw.com/webcast/jeff113/abeo/index.aspx
Abeona Recent
HighlightsMay 31st: Opening of Commercial Gene
& Cell Therapy GMP Manufacturing Facility in Cleveland,
Ohio-- The Elisa Linton Center for Rare Disease Therapies
to support development of advanced gene and cell therapies for
treatment of serious rare diseases.-- The GMP facility will have
the capability to manufacture clinical and commercial grade
products over Abeona’s multiple programs, including recessive
dystrophic epidermolysis bullosa (RDEB) and Sanfilippo
syndrome.
May 18th: Clinical Update on MPS IIIA
Gene Therapy Trial at the 21st Annual ASGCT Meeting--
Ongoing ABO-102 (AAV-SGSH) trial results demonstrate robust and
durable clinical effects achieved throughout various timepoints
post-administration.-- 18-month efficacy and safety data continue
to demonstrate time- and dose-dependent reductions in underlying
disease pathology, including decreased CSF and urine GAGs and
improved liver volumes.-- 11 subjects enrolled through > 4,200
days cumulative follow up.
May 17th: Clinical Update from RDEB Gene
& Cell Therapy Trial at the 21st Annual ASGCT
Meeting-- EB-101, the Company’s gene-corrected skin graft
cell therapy for patients suffering from RDEB is safe and
well-tolerated, with durable efficacy.-- Trial results demonstrate
robust and durable clinical effects achieved throughout various
timepoints post-administration.-- Completed Phase 1/2 clinical
trial included seven patients with 42 gene-corrected EB-101 grafts,
with the first patient treated over three years ago with lasting
effects and closed wounds to date.
About Abeona: Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing cell and gene therapies for life- threatening rare
genetic diseases. Abeona's lead programs include EB-101
(gene-corrected skin grafts) for recessive dystrophic epidermolysis
bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)
based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and
ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene
therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also
developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease,
ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for
epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia
(FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene
editing approach to gene therapy for rare blood diseases. In
addition, Abeona is developing a proprietary vector platform, AIM™,
for next generation product candidates. For more information, visit
www.abeonatherapeutics.com.
Investor Contact:Christine SilversteinSVP,
Investor Relations & Finance Abeona Therapeutics Inc.+1 (646)
813-4707csilverstein@abeonatherapeutics.com
Media Contact:Lynn GranitoBerry
& Company Public Relations+1 (212)
253-8881lgranito@berrypr.com
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain
necessary regulatory approvals and licenses; the impact of changes
in the financial markets and global economic conditions; and other
risks as may be detailed from time to time in the Company's Annual
Reports on Form 10-K and other reports filed by the Company with
the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise.
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2024 to May 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From May 2023 to May 2024